
NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …
Patients with advanced soft tissue sarcoma could now benefit from PharmaMar’s new drug trabectedin, after the NICE granted its approval. …

